HLA-class II haplotype associations with ovarian cancer

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2980-2985

  Kübler, Kirsten ^a   Arndt, Peter F ^b   Wardelmann, Eva ^a   Krebs, Dieter ^a   Kuhn, Walther ^a   Van Der Ven, Katrin ^a  

^a UNIVERSITY OF BONN   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

Genetic susceptibility; HLA class II loci; MHC; Ovarian cancer

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CAUCASIAN; CELL INTERACTION; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; ALLELES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 33751572640     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22266     Document Type: Article

References (33)

1. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909;5:273-90.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
3. Salih HR, Nussler V. Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res 2001;6:323-32.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
5. Forbes SA, Trowsdale J. The MHC quarterly report. J Immunogenet 1999;50:152-9.
6. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-50.
7. Wassmuth R. HLA/MHC class II gene regulation. In: McMichael AJ, ed. HLA and MHC: genes, molecules, function. Oxford: BIOS Scientific Publishers, 1996.249-76.
8. Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Charron D, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T et al. Nomenclature for factors of the HLA system, 1995. Tissue Antigens 1995;46:1-18.
9. Dawins RL, Christiansen FT, Kay PH, Garlepp M, NcCluskey J, Hollingsworth PN, Zilko PJ. Disease associations with complotypes, supratypes and haplotypes. Immunol Rev 1983;70:5-22.
10. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specifity. Nat Genet 1994;6:157-62.
11. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci USA 2000;97:11451-4.
12. Pecorelli S, Benedet JL, Creasman WT, Shephard JH, Pettersson F. Annual report on the results of treatment in gynecological cancer. Oxford: International Federation of Gynecology and Obstetrics, 1998.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
14. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and HLA-DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993;41:119-34.
15. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens 1992;39:225-35.
16. Svejgaard A, Jersild C, Nielsen LS, Bodmer WF. HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens 1974;4:95-105.
17. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Geraghty DE, Hansen JA, Hurley CK, Mach B, Mayr WR, Parham P, et al. Nomenclature for Factors of the HLA System, 2004. Hum Immunol 2005;66:571-636.
18. Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL, Erlich HA, Klitz W. Polymorphism, recombination, and linkage desiquilibrium within the HLA class II region. J Immunol 1992;148:249-58.
19. Best CL, Pudney J, Welch WR, Burger N, Hill JA. Localization and characterization of white blood cell populations within the human ovary throughout the menstrual cycle and menopause. Hum Reprod 1996;11:790-7.
20. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
21. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. Cytotoxic T-cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993;151:225-34.
22. Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, Schwartzentruber DJ. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996;2:263.
23. Cuccia M, Finco O, Martinetti M, Babilonti L, Bolis PF. HLA supratypes in Ovarian Cancer (a preliminary report on 52 cases). Med Biol Env 1989;17:89-94.
24. Illeni MT, Pasquali M, La Monica G, Böhm S, Rovini D, Di Re E. HLA Antigens in ovarian adenocarcinoma patients. Eur J Gynaecol Oncol 1985;6:121-5.
25. Rammensee HG, Friede T, Stefanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;44:351-7.
26. Salazar M, Deulofeut H, Granja C, Deulofeut R, Yunis DE, Marcus-Bagley D, Awdeh Z, Alper CA, Yunis EJ. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics 1995;41:366-74.
27. Mu H, King MC, Criswell LA. Relative predispositional effects and mode of inheritance of HLA-DRB1 alleles among community-based Caucasian females with rheumatoid arthritis. Genet Epidemiol 1998;15:123-34.
28. Doherty DG, Vaughan RW, Donaldson PT, Mowat AP. HLA DQA, DQB and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids. Hum Immunol 1992;34:53-63.
29. Salazar M, Varela A, Ramirez LA, Uribe O, Vasquez G, Egea E, Yunis EJ, Iglesias-Gamarra A. Association of HLA-DRB1*1602 and DRB1*1001 with Takayasu arteritis in Colombian mestizos as markers of Amerindian ancestry. Int J Cardiol 2000;75 (Suppl 1):S113-S116.
30. Taneja V, Giphart MJ, Verduijn W, Naipal A, Malaviya AN, Mehra NK. Polymorphism of HLA-DRB, -DQA1, and -DQB1 in rheumatoid arthritis in Asian Indians: association with DRB1*0405 and DRB1*1001. Hum Immunol 1996;46:35-41.
31. Dorak MT, Lawson T, Machulla HK, Darke C, Mills KI, Burnett AK. Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood 1999;94:694-700.
32. Bernal A, Mendez-Moran L, Fajardo-Gutierrez A, Gonzalez-Lira G, Escudero P, Ortiz H. Univariate and multivariate analysis of risk factors for ovarian cancer: case-control study, Mexico city. Arch Med Res 1995;26:245-9.
33. Ho H, Gill TJ, III, Nsieh R, Hsieh C, Yang Y, Lee T. The prevalence of recurrent spontaneous abortions, cancer, and congenital anomalies in the families of couples with recurrent spontaneous abortions or gestational trophoblastic tumors. Am J Obstet Gynecol 1991;165:461-6.